Citations Citations to this article as recorded by Selective DrugFree Active Surveillance in Ulcerative Colitis: BiomarkerGuided, PatientCentered Approach Tsutomu Nishida, Naoto Osugi, Takahiro Amano, Takeo Yoshihara JGH Open.2026;[Epub] CrossRef Therapeutic Impact on Quality of Life in Adult Patients With Chronic Intestinal Pseudo-obstruction: A Multicenter, Cohort Study Kota Takahashi, Takaomi Kessoku, Hidenori Ohkubo, Yo Ishihara, Kosuke Tanaka, Tomoki Ogata, Tsumugi Jono, Atsushi Yamamoto, Anna Ozaki, Yuki Kasai, Michihiro Iwaki, Akiko Fuyuki, Takayuki Kato, Yasunari Sakamoto, Takeo Kurihashi, Hirotoshi Ebinuma, Atsush Journal of Neurogastroenterology and Motility.2026
Honestly refreshing
4 One such instance for which states have this flexibility is for agents when used for anorexia, weight loss, or weight gain. Hence, states that participate in MDRP are not required to cover agents for weight loss and may elect not to cover anti-obesity medications (AOMs) such as Saxenda, Wegovy, and Zepbound for their weight loss indications
PMID 18177777
With your specific weight loss goals and metabolic profile front and center, and if appropriate, your provider will prescribe you a treatment plan you can stick with and that works
Local Supply Chain Updates Indianapolis healthcare providers are getting creative with their supply management
